CCL4 and neoplasm: discovered that Rh‐1, a novel inhibitor of the Wnt/β‐catenin pathway, can upregulate CCL4 to promote T‐cell infiltration into tumor tissue and synergize with PD‐1 therapy.[17, 18] Therefore, we explored whether targeting circFADS1 could induce similar immune‐related changes.